NFKB1 and diabetes mellitus: Since P2X7 receptor is integral in the processing and release of many inflammatory mediators (IL-1β, NFκB, TNFα etc.), the inhibition of this receptor may provide therapeutic benefit in diseases including cancer, tuberculosis, diabetes, asthma, and all of the neurodegenerative diseases.